Recent News and Articles on the Keywords: hypertension + pulmonary + 0.37  Related to the article below (Last Update: 8/7/2008)

EU Extends Indication of Bosentan to Pulmonary Arterial ... DG News - ... for the treatment of patients with mildly symptomatic pulmonary arterial hypertension (PAH World Health Organization [WHO] functional class [FC] II). ... Design of the REVEAL Registry for US Patients With Pulmonary ... RedOrbit, TX - Aug 5, 2008 The Surveillance of North American Pulmonary Hypertension (SNAP)5 and the Surveillance of Pulmonary Hypertension in America (SOPHLA)6 registries were ... Actelion Wins European Approval for Pulmonary Arterial ... RedOrbit, TX - Aug 5, 2008 Tracleer is claimed to be the first pulmonary arterial hypertension (PAH) treatment ever to be investigated in a clinical study that exclusively enrolled ...VTX:ATLN Tracleer? (bosentan) receives EU approval for treatment of ... Ad-Hoc-News (Pressemitteilung), Germany - Aug 3, 2008 Class II patients are defined as patients with pulmonary hypertension resulting in mild limitation of physical activity, they are comfortable at rest and ...VTX:ATLN Bosentan Improves Quality Of Life For Patients With Pulmonary ... Science Daily (press release) - Jul 23, 2008 31, 1969) ? Recent studies have shown that bosentan therapy greatly improves the quality of life for patients with pulmonary arterial hypertension (PAH). ... Sleep well Southtown Star, IL - Aug 5, 2008 Now Sahloul is trying to help people rest easy at the new Southwest Sleep Center and Pulmonary Consultants in Oak Lawn. According to Sahloul, a sleep ... Endothelin Antagonist Trial in Mildly Symptomatic Pulmonary ... Medscape (subscription) - Jul 31, 2008 Pulmonary arterial hypertension (PAH) is characterized by progressive pulmonary arterial vasoconstriction and remodeling, leading to a marked rise in ... The FDA's Black Box Forbes, NY - 47 minutes ago ... three "approvable" letters from the FDA requesting more study on a drug to treat a rare disease called pulmonary hypertension, the last in 2007. ...SGP - OTC:SHRGY The Money Times Uninsured And Chronically ill: The New American Health Risk The Money Times, India - Aug 5, 2008 ... ambit of the study include cardiovascular disease, hypertension, diabetes, asthma, high cholesterol, chronic obstructive pulmonary disease and cancer. ... One-Third of Uninsured Are Chronically Ill U.S. News & World Report Chronic conditions afflict millions of uninsured adults McKnight's Long Term Care News Comment by Karen Davis, Ph.D. President, The Commonwealth Fund all 39 news articles » Pulmonary Arterial Hypertension More Severe in Carriers of BMPR2 ... Abkhazia, CA - Jul 24, 2008 Among patients with pulmonary arterial hypertension (PAH), those with germline mutations in the gene encoding bone morphogenetic protein receptor 2 (BMPR2) ...

Antidepressants linked to increased risk of persistent pulmonary hypertension in newborns

A University of California, San Diego ( UCSD ) School of Medicine collaborative study with Boston University's Slone Epidemiology Center found an increased risk of persistent pulmonary hypertension in newborns of mothers who used certain commonly prescribed antidepressants in late pregnancy.

The results of the study are published in the New England Journal of Medicine.

Persistent pulmonary hypertension is a serious condition that typically involves severe respiratory failure in a newborn infant and requires immediate treatment. The condition occurs in about one to two per thousand babies.

The new study findings indicate that pregnant women who take one of the antidepressants known as selective serotonin reuptake inhibitors or SSRIs, such as Fluoxetine ( Prozac ), Paroxetine ( Paxil ) or Sertraline ( Zoloft ), in the second half of pregnancy have a small but significantly increased chance of delivering an infant who develops persistent pulmonary hypertension.

The study found that exposure to antidepressants other than SSRIs did not pose a risk for persistent pulmonary hypertension.
In addition, women who discontinued use of SSRIs in the first half of pregnancy did not have an increased risk of delivering a child with the condition.

These findings may be important for pregnant women and clinicians when making decisions about the most appropriate treatments for depression late in pregnancy.

Lead author on the study, Christina Chambers, of the Departments of Pediatrics and Family and Preventive Medicine at UCSD, worked with a team of investigators who identified at birth 377 infants with persistent pulmonary hypertension and 836 normal newborns from 97 delivery hospitals in four metropolitan centers in the U.S. and Canada between 1998 and 2003.
The study was part of the ongoing Birth Defects Surveillance Program being conducted by the Slone Epidemiology Center with the collaboration of 17 San Diego County hospitals including UCSD Medical Center.

Within six months after birth, the researchers examined the records and carefully interviewed the mothers of children with persistent pulmonary hypertension and the mothers of the matched control infants selected from the same hospitals. The mothers in both groups were asked specifically about the use of any antidepressant medications during pregnancy, the names of products used, and the timing in gestation when the mother used the medication. Mothers were also queried about a wide variety of other maternal exposures, medical history, pregnancy history, and lifestyle factors.

" Based on our findings, we estimate that six to twelve mothers per thousand who use an SSRI after 20 weeks' gestation, are likely to deliver a child with persistent pulmonary hypertension," said Chambers. " Put in practical terms, the risk is relatively low -- about 99 percent of women exposed to one of these medications during the latter half of pregnancy will deliver an infant unaffected by persistent pulmonary hypertension."